Viyash Scientific Acquires 100% Stake in Italian Animal Health Firm BioForLife Italia
Viyash Scientific Ltd has entered into a binding agreement for the acquisition of 100% shareholding in BioForLife Italia s.r.l., an established player in the animal health sector. The deal is designed to strengthen and scale the company’s presence within the companion animal segment in Italy through the acquired entity's existing platform, customer reach, and product capabilities.The acquisition targets BioForLife Italia s.r.l., based in Milan, Italy. The total consideration for the transaction amounts to EUR 16.975 million. This aggregate amount is structured with EUR 15.0 million payable upon closing, and a deferred consideration of EUR 1.975 million, which will be settled according to the terms defined in the transaction documents.
The target company operates in the pharmaceuticals industry, specializing in the marketing and distribution of veterinary products for companion animals. Products managed by BioForLife include medicines, nutraceuticals, and testing kits. The acquisition does not involve related party transactions, and neither Viyash Scientific nor its promoters have any vested interest in the acquired entity.
Strategic growth is a key element of this transaction. By acquiring BioForLife Italia s.r.l., Viyash aims to secure an established front-end platform within the Italian market for companion animal care.
Key details regarding the acquisition and the target company are summarized below:
| Aspect | Detail |
|---|---|
| Target Company | BioForLife Italia s.r.l., Milan, Italy |
| Industry | Pharmaceuticals - Animal Health / Veterinary Products |
| Acquisition Purpose | Strengthening and scaling the company’s presence in Italy in the companion animal segment |
| Total Consideration | EUR 16.975 million |
| Shareholding Acquired | 100% |
BioForLife Italia s.r.l., incorporated on March 24, 2010, has demonstrated steady growth over the last three calendar years. Its reported annual sales figures stand as follows:
| Year | Annual Sales |
|---|---|
| CY 2023 | €7.1 Million |
| CY 2024 | €8.3 Million |
| CY 2025 | €9.0 Million (Approximate) |
The acquisition is subject to the fulfillment of all applicable conditions precedent, which includes notification under Italian Golden Power Laws (Decree-Law No. 21/2012). The initial closing of the transaction is expected within three months from the execution of the binding agreement.
VIYASH Stock Price Movement
Shares of Viyash Scientific Limited are shedding 0.74% as of 12:47 PM, trading at ₹253.35 with a recorded change of ₹1.90 per share. The stock trades within an intraday range from ₹248.00 to ₹257.50 and has seen 1.34 million shares traded so far today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.